Monday, July 8, 2019

SPARC gets orphan drug designation from USFDA for novel kinase inhibitor

SPARC gets orphan drug designation from USFDA for novel kinase inhibitor The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 2 lakh people in the US, Sun Pharma Advanced Research Company (SPARC) said in a filing to BSE.

from Moneycontrol Business News https://ift.tt/2L8Hplf
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Market moves driven more by psychology than fundamentals: Samir Arora

Indian stock markets are caught between global worries and strong domestic company profits. Foreign investor activity, oil price swings, and...